Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk

Journal of Clinical Oncology

Volumn 24, Issue 31, 2006, Pages 5010-5016

  Cai, Qiuyin ^a   Gao, Yu Tang ^a   Chow, Wong Ho ^a   Shu, Xiao Ou ^a   Yang, Gong ^a   Ji, Bu Tian ^a   Wen, Wanqing ^a   Rothman, Nathaniel ^a   Li, Hong Lan ^a   Morrow, Jason D ^a   Zheng, Wei ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN E2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CHINESE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; URINALYSIS; CASE CONTROL STUDY; CHINA; COLORECTAL TUMOR; MIDDLE AGED; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; URINE;

ADULT; AGED; CASE-CONTROL STUDIES; CHINA; COLORECTAL NEOPLASMS; DINOPROSTONE; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750956437     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.4931     Document Type: Article

References (42)

1. Weitz J, Koch M, Debus J, et al: Colorectal cancer. Lancet 365:153-165, 2005
2. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488, 2005
3. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
4. Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002
5. Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217, 2005
6. Balkwill F, Mantovani A: Inflammation and cancer: Back to Virchow? Lancet 357:539-545, 2001
7. Munkholm P: Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18:1-5, 2003 (suppl 2)
8. Panes J: Inflammatory bowel disease: Pathogenesis and targets for therapeutic interventions. Acta Physiol Scand 173:159-165, 2001
9. Vagefi PA, Longo WE: Colorectal cancer in patients with inflammatory bowel disease. Clin Colorectal Cancer 4:313-319, 2005
10. Itzkowitz SH, Yio X: Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7-G17, 2004
11. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266, 2002
12. Chan TA: Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3:166-174, 2002
13. Baron JA: Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37:1-24, 2003
14. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899, 2003
15. Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993
16. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000
17. Wendum D, Masliah J, Trugnan G, et al: Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 445:327-333, 2004
18. Brown JR, DuBois RN: COX-2: A molecular target for colorectal cancer prevention. J Clin Oncol 23:2840-2855, 2005
19. Gupta RA, DuBois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1:11-21, 2001
20. Huls G, Koornstra JJ, Kleibeuker JH: Nonsteroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362: 230-232, 2003
21. Kashfi K, Rigas B: Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70:969-986, 2005
22. Wu KK: Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot Essent Fatty Acids 72:89-93, 2005
23. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:18075-18081, 2001
24. 2 in human colon cancer cells. Cancer Res 58:362-366, 1998
25. Tsujii M, Kawano S, Tsuji S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716, 1998
26. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94:3336-3340, 1997
27. Kojima M, Morisaki T, Uchiyama A, et al: Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol 8:458-465, 2001
28. Rigas B, Goldman IS, Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122:518-523, 1993
29. 2 synthesis in healthy humans and those with lung cancer. Anal Biochem 334:266-275, 2004
30. Zheng W, Chow WH, Yang G, et al: The Shanghai Women's Health Study: Rationale, study design, and baseline characteristics. Am J Epidemiol 162:1123-1131, 2005
31. Greenland S, Thomas DC: On the need for the rare disease assumption in case-control studies. Am J Epidemiol 116:547-553, 1982
32. Harrell F: Regression Modeling Strategies. New York, NY, Springer, 2001
33. Eberhart CE, Coffey RJ, Radhika A, et al: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188, 1994
34. Elder DJ, Baker JA, Banu NA, et al: Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol 198:428-434, 2002
35. Hao X, Bishop AE, Wallace M, et al: Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 187:295-301, 1999
36. Watanabe K, Kawamori T, Nakatsugi S, et al: Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59:5093-5096, 1999
37. Hansen-Petrik MB, McEntee MF, Jull B, et al: Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 62:403-408, 2002
38. 2 administration. Carcinogenesis 24:985-990, 2003
39. Yoshimatsu K, Golijanin D, Paty PB, et al: Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7:3971-3976, 2001
40. Backlund MG, Mann JR, Holla VR, et al: 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280: 3217-3223, 2005
41. Yan M, Rerko RM, Platzer P, et al: 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 101:17468-17473, 2004
42. Wacholder S, Hartge P, Lubin JH, et al: Non-differential misclassification and bias towards the null: A clarification. Occup Environ Med 52:557-558, 1995